News & Events about Summit Therapeutics Inc.
Ticker Report
2 months ago
Summit Therapeutics Inc. (NASDAQ:SMMT Get Rating) CEO Mahkam Zanganeh bought 15,973,743 shares of the businesss stock in a transaction that occurred on Wednesday, March 8th. The stock was purchased at an average cost of $1.05 per share, with a total value of $16,772,430.15. Following ...
Business Wire
2 months ago
Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit, we, or the Company) today announced the successful closing of its fully-subscribed $500 million rights offering. The rights offering resulted in the sale of approximately 476.2 million shares of the Companys common stock, par value $0.01, at a price...
Globe Newswire
3 months ago
PHILADELPHIA, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit) on behalf of the Companys shareholders. The investigation seeks to determine whether Summit has issued false and misleading statements and/or failed to ...
Globe Newswire
3 months ago
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit) investors that the firm has initiated an investigation into whether Summit issued ...
Globe Newswire
4 months ago
PHILADELPHIA, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Summit Therapeutics Inc. (NASDAQ: SMMT) (Summit) on behalf of the Companys investors. The investigation seeks to determine whether Summit issued false and misleading statements and/or failed to ...